Rabbit and dog (IVT ocular studies); rat and cynomolgus monkey (7-day IV); monkey the only pharmacologically relevant species
“The monkey is the only species identified that could be considered relevant showing 1/10th of the ARC1905 in an in vitro activity assay against human C5.”
✓ VerifiedFDA pharmacology/toxicology review, p. 35Source ↗
Why that species
Human C5 aptamer: monkey 1/10th and rat 1/1000th of human activity; rabbit/dog expected very low activity but accepted for ocular tolerability
“The ocular studies were conducted in rabbit and dogs, which, as the Applicant indicated, are species in which ARC1905 is expected to have very low activity.”
✓ VerifiedFDA pharmacology/toxicology review, p. 35Source ↗
Surrogate molecule
No surrogate; clinical aptamer (ARC1905) tested in non-pharmacologically-relevant ocular species plus IV monkey
“There are no animal species in which the human anti-C5 aptamer can be tested in ocular toxicity studies for effects stemming from C5 binding.”
✓ VerifiedFDA pharmacology/toxicology review, p. 36Source ↗
Species: general tox
New Zealand White rabbit and Beagle dog (repeat-dose intravitreal)
“Repeat-dose IVT toxicity studies were conducted in New Zealand White rabbits (0, 0.15, 0.5, and 1.5 mg/eye) and Beagle dogs (0, 0.3, 1, and 3.0 mg/eye).”
✓ VerifiedFDA pharmacology/toxicology review, p. 7Source ↗
Species: DART
Rat and rabbit (EFD only); fertility and pre/postnatal studies waived
“In the embryofetal development (EFD) toxicity studies in rats and rabbits, there was no avacincaptad pegol-related adverse effects on any measured maternal or fetal parameter at doses up to 1.2 mg/kg/day (NOAEL).”
✓ VerifiedFDA pharmacology/toxicology review, p. 8Source ↗
Species: carcinogenicity
Not conducted (waiver)
“No studies were conducted. The Applicant submitted a justification to support a waiver request not to conduct the carcinogenicity studies”
✓ VerifiedFDA pharmacology/toxicology review, p. 69Source ↗
Surrogate used in
No surrogate used; no species allows testing of C5-related ocular effects
“There are no animal species in which the human anti-C5 aptamer can be tested in ocular toxicity studies for effects stemming from C5 binding.”
✓ VerifiedFDA pharmacology/toxicology review, p. 36Source ↗